Soria JC - Search Results

1

Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis.

Ma X, Le Teuff G, Lacas B, Tsao MS, Graziano S, Pignon JP, Douillard JY, Le Chevalier T, Seymour L, Filipits M, Pirker R, Jänne PA, Shepherd FA, Brambilla E, Soria JC, Hainaut P; LACE-Bio Collaborative Group. Ma X, et al. Among authors: soria jc. J Thorac Oncol. 2016 Jun;11(6):850-61. doi: 10.1016/j.jtho.2016.02.002. Epub 2016 Feb 17. J Thorac Oncol. 2016. PMID: 26899019 Free article. Clinical Trial.

2

[Inappropriate antidiuretic hormone secretion disclosing a second primary lung cancer 5 years after complete remission of a small cell lung carcinoma].

Soria JC, Fizazi K, Merad M, Le Chevalier T. Soria JC, et al. Bull Cancer. 1996 Aug;83(8):605-8. Bull Cancer. 1996. PMID: 8869039 French.

3

Squamous cell carcinoma of the penis: multivariate analysis of prognostic factors and natural history in monocentric study with a conservative policy.

Soria JC, Fizazi K, Piron D, Kramar A, Gerbaulet A, Haie-Meder C, Perrin JL, Court B, Wibault P, Théodore C. Soria JC, et al. Ann Oncol. 1997 Nov;8(11):1089-98. doi: 10.1023/a:1008248319036. Ann Oncol. 1997. PMID: 9426328 Free article.

4

Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication.

Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK, Mao L. Soria JC, et al. Cancer Res. 2000 Aug 1;60(15):4000-4. Cancer Res. 2000. PMID: 10945597

5

Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer.

Le Chevalier T, Brisgand D, Soria JC, Douillard JY, Pujol JL, Ruffie P, Aberola V, Cigolari S. Le Chevalier T, et al. Among authors: soria jc. Oncologist. 2001;6 Suppl 1:8-11. doi: 10.1634/theoncologist.6-suppl_1-8. Oncologist. 2001. PMID: 11181998 Free article. Clinical Trial.

6

Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?

Soria JC, Brisgand D, Le Chevalier T. Soria JC, et al. Ann Oncol. 2001 Dec;12(12):1667-70. doi: 10.1023/a:1013574413217. Ann Oncol. 2001. PMID: 11843242 Free article. Clinical Trial.

7

Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.

Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, Liu DD, Kurie JM, Mao L, Khuri FR. Soria JC, et al. Clin Cancer Res. 2002 May;8(5):1178-84. Clin Cancer Res. 2002. PMID: 12006535

8

hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer.

Wang L, Soria JC, Kemp BL, Liu DD, Mao L, Khuri FR. Wang L, et al. Among authors: soria jc. Clin Cancer Res. 2002 Sep;8(9):2883-9. Clin Cancer Res. 2002. PMID: 12231532

9

Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer.

Soria JC, Moon C, Kemp BL, Liu DD, Feng L, Tang X, Chang YS, Mao L, Khuri FR. Soria JC, et al. Clin Cancer Res. 2003 May;9(5):1785-91. Clin Cancer Res. 2003. PMID: 12738735

10

Imatinib in small cell lung cancer.

Soria JC, Johnson BE, Chevalier TL. Soria JC, et al. Lung Cancer. 2003 Aug;41 Suppl 1:S49-53. doi: 10.1016/s0169-5002(03)00142-9. Lung Cancer. 2003. PMID: 12867062 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

732 results

Search Page